Immuani develops solutions for oncology treatments and auto-immune disorders by utilizing AI and ML technology to assist in mapping and to provide insights into the reprogramming of the immune system.
Immunai does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.
The stock price for Immunai will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 10/27/2021 | Series C-1 and C-2 | $1.15B | $XXX.XX | $XXX.XX |
| 2/11/2021 | Series B-1 and B-2 | $240.97MM | $XXX.XX | $XXX.XX |
| 5/14/2020 | Series A, Seed-1, and Seed-2 | $38.16MM | $XXX.XX | $XXX.XX |
If you own Immunai pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
Immunai is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
